CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia…
Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.
Volume 167, issue 2 articles listing for Journal of Neuro-Oncology
JCO Oncology Advances (JCO OA) is a fully open-access, online-only, and interdisciplinary journal committed to accelerating progress in the global fight against cancer. By providing…
Researchers investigated whether listening to mindfulness audio recordings may alleviate the side effects of radiation therapy in men with prostate cancer.
AICR provides the 10 Cancer Prevention Recommendations as a blueprint to help people reduce their cancer risk.
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Mark D. Tyson, II, MD, MPH, concludes his conversation on the BOND-003 trial by discussing the next steps for research on cretostimogene grenadenorepvec.